SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN

Core Viewpoint - Agenus Inc. is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop after an unfavorable FDA meeting regarding its immunotherapy combination [1][2]. Group 1: Company Developments - On July 18, 2024, Agenus announced the results of its end-of-Phase 2 meeting with the FDA concerning its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for treating adult patients with relapsed/refractory microsatellite stable colorectal cancer [2]. - The FDA advised against the submission of results for Accelerated Approval, indicating that the objective response rates may not translate to a survival benefit [2]. Group 2: Market Reaction - Following the FDA's announcement, Agenus's stock price fell by $10.43 per share, representing a decline of 58.83%, closing at $7.30 per share on July 18, 2024 [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Agenus, focusing on potential securities fraud or other unlawful business practices by the company and its officers or directors [1].